

Exhibit A

BOX ISSUE FEE

Assistant Commissioner for Patents Mailed: 10/29/98
Washington, D.C. 20231 Docket No.: PF-0233 US

Applicants: GOLI et al.

Serial No.: 08/822,264

Filing Date: March 20, 1997

Title: **A POLYNUCLEOTIDE ENCODING A NOVEL
HUMAN CYTOKINE/STEROID RECEPTOR (AS
AMENDED)**

Enclosed are the following:

1. Issue Fee Transmittal (1 p., in duplicate);
2. Amendment Pursuant to CFR 1.312(a) (4 pp.);
3. Information Disclosure Statement (3 pp.);
4. Applicants' List of References (PTO 1449) (1 p.);
5. Associate Power of Attorney (1 p.); and
6. Copy of Int'l Search Report (4 pp.)
7. Copy of References 1-6.

SMP:ww

BOX ISSUE FEE

Assistant Commissioner for Patents Mailed: 10/29/98
Washington, D.C. 20231 Docket No.: PF-0233 US

Applicants: GOLI et al.

Serial No.: 08/822,264

Filing Date: March 20, 1997

Title: **A POLYNUCLEOTIDE ENCODING A NOVEL
HUMAN CYTOKINE/STEROID RECEPTOR (AS
AMENDED)**

Enclosed are the following:

1. Issue Fee Transmittal (1 p., in duplicate);
2. Amendment Pursuant to CFR 1.312(a) (4 pp.);
3. Information Disclosure Statement (3 pp.);
4. Applicants' List of References (PTO 1449) (1 p.);
5. Associate Power of Attorney (1 p.); and
6. Copy of Int'l Search Report (4 pp.)
7. Copy of References 1-6.

SMP:ww

NOV 02 1998

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Assistant Commissioner for Patents,
Washington, D.C. 20231 on October 29, 1998
By: *Wanda Warren*
Printed: Wanda Warren

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Goli et al.

Title: **A POLYNUCLEOTIDE ENCODING A NOVEL HUMAN CYTOKINE/STEROID RECEPTOR (AS AMENDED)**

Serial No.: 08/822,264 Filing Date: March 20, 1997

Batch No.: **H33** Group Art Unit: 1646

Examiner: M. Pak

Assistant Commissioner for Patents
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT
WITH CERTIFICATION UNDER § 1.97(e)(1)**

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure. The documents were cited in the International Search Report for the corresponding PCT Application No. PCT/US 98/06045, mailed September 7, 1998.

The undersigned hereby certifies in accordance with 37 C.F.R. 1.97(e)(1) that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

In view of the status of the subject application, pursuant to 37 C.F.R. 1.97(d), Applicants hereby request consideration of this Information Disclosure Statement with Certification and Fee under 37 C.F.R. 1.97(e)(1).

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.


Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108** the Petition fee of **\$130.00** under 37 C.F.R. 1.17(i). The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. **09-0108**. A duplicate copy of this communication is enclosed.

If there are any questions regarding the above, the Examiner is invited to call the undersigned attorney at 650-845-4842.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: October 29, 1998



Sheela Mohan-Peterson, Esq.
Reg. No. 41,201

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 845-4842
Fax: (650) 849-8886

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0233 US	08/822,264
LIST OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)		Applicant(s) GOLI et al.
	Filing Date	Group
	March 20, 1997	1646

U.S. Patent Documents

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents

		Document	Date	Country	Class	Subclass	Translation Yes	No
	1.	98 10291	03/12/98	WO	G01N	33/574	X	
	2.	196 27 237	1998	DE				X

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Referrals as of 5/12/98	3.	Hillier, L., et al., "The WashU-Merck EST Project," Database EMEST9, E.M.B.L. Databases, Accession No. AA081900, XP002074762, January 14, 1997.
Referrals as of 5/12/98	4.	Hillier, L., et al., "The Merck-WashU EST Project," Database EMEST6, E.M.B.L. Databases, Accession Number W56474, June 8, 1996.
Referrals as of 5/12/98	5.	Hillier, L., et al., "WashU-NCI human EST project," Database R54U006, E.M.B.L. Databases, Accession Number AA166645, XP002074764, December 21, 1996.
Referrals as of 5/12/98	6.	Falkenstein, E., et al., "H. Sapiens mRNA for putative Progesterone Binding Protein," Database EMHUM2, E.M.B.L. Databases, Accession Number Y12711, XP002074765, April 30, 1997.

Examiner _____ Date Considered _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.